• Shopping Cart
    There are no items in your cart

ISO 10993-17:2023

Current

Current

The latest, up-to-date edition.

Biological evaluation of medical devices — Part 17: Toxicological risk assessment of medical device constituents

Available format(s)

Hardcopy , PDF

Language(s)

English, French

Published date

13-09-2023

€217.00
Excluding VAT
Summarise this standard

This document specifies the process and requirements for the toxicological risk assessment of medical device constituents. The methods and criteria used to assess whether exposure to a constituent is without appreciable harm are also specified. The toxicological risk assessment can be part of the biological evaluation of the final product, as described in ISO 10993-1.

The process described in this document applies to chemical characterization information obtained in line with ISO10993-18. When a toxicological risk assessment of either the compositional information or analytical chemistry data (e.g. extractable data or leachable data) are required to determine whether the toxicological risks related to the constituents are negligible or tolerable.

The process described in this document is not intended to apply to circumstances where the toxicological risk has been estimated by other means, such as:

— constituents, excluding cohort of concern or excluded chemicals, that are present in or extracted from a medical device at an amount representative of patient exposure below a relevant, toxicologically-based reporting threshold (see applicable requirements in ISO10993-18:2020, AnnexE and ISO/TS21726);

— a new or changed medical device for which chemical or biological equivalence has been established with an existing biocompatible or clinically established medical device (see applicable requirements in ISO10993-18:2020, AnnexC).

The process described in this document is also not applicable to:

— medical device constituents that do not contact the body (e.g. in vitro diagnostics);

— biological risks associated with physical interactions of the medical device with the body (i.e. application of mechanical forces, energy or surface morphology, etc.), provided that the chemical exposure is not changed;

— active pharmaceutical ingredients of device-drug combination products or biologic components of device-biologic combination products as additional regulatory considerations can apply;

— exposure to a particular constituent that arises from sources other than the device, such as food, water or air.

Committee
ISO/TC 194
DocumentType
Standard
Pages
65
PublisherName
International Organization for Standardization
Status
Current

Frequently Asked Questions

ISO 10993-17 is International Organization for Standardization (ISO)'s standard for biological evaluation of medical devices, while ISO 11607-2 covers terminally sterilised medical device packaging (International). ISO 10993-17 provides requirements or test guidance for evaluating biological risks associated with patient-contacting medical devices. ISO 11607-2 specifies requirements for sterile barrier systems and packaging process validation for terminally sterilised medical devices.

ISO 10993-17 is an international standard published by International Organization for Standardization (ISO), and is applied internationally rather than in a single country.

ISO 10993-17 is published by International Organization for Standardization (ISO). It is an international standard.

ISO 10993-17 belongs to the topic area of biological evaluation of medical devices. It is an international standard published by International Organization for Standardization (ISO).

ISO 10993-17 provides requirements or test guidance for evaluating biological risks associated with patient-contacting medical devices. It is an international standard published by International Organization for Standardization (ISO).
€217.00
Excluding VAT